Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 11;16(7):523–535. doi: 10.1161/CIRCIMAGING.123.015259

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Circulation: Cardiovascular Imaging is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 1. — ^99mTechnetium labeled 3,3-diphosphono-1,2-propanodicarboxylic acid (^99mTc-DPD) scintigraphy and echocardiographic images of patients with Apo AI cardiac amyloidosis. Patient 1=^99mTc-DPD scintigraphy and single-photon emission computed tomography (SPECT) images demonstrating grade 1 cardiac uptake with prominent right atrial uptake (arrows). Patient 2=^99mTc-DPD scintigraphy and SPECT images demonstrating grade 1 cardiac uptake with prominent right ventricular uptake (arrows). Patient 3=Transthoracic echocardiography demonstrating marked thickening of the tricuspid valve leaflets (arrows) and subvalvular apparatus and biventricular hypertrophy. Patient 4=Transthoracic echocardiography demonstrating severe tricuspid regurgitation. Patient 5=Transthoracic echocardiography demonstrating tricuspid stenosis (arrows), with turbulent forward flow through the tricuspid valve, biatrial enlargement, and biventricular hypertrophy.